Logo

ONCY

Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc. • NASDAQ
$1.00 ▼ -4.15% (-0.04)
Market Cap $100.04 M
52w High $1.51
52w Low $0.33
Dividend Yield 0%
P/E -3.44
Volume 1.42M
Outstanding Shares 100.36M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $13.84M ▲ $-14.4M ▼ 0% $-0.14 ▼ $-14.559M ▼
Q2-2025 $0 $5.706M ▼ $-6.165M ▲ 0% $-0.068 ▲ $-5.612M ▲
Q1-2025 $0 $6.999M ▼ $-6.687M ▲ 0% $-0.079 ▲ $-6.902M ▲
Q4-2024 $0 $8.437M ▼ $-8.017M ▲ 0% $-0.1 ▲ $-8.339M ▲
Q3-2024 $0 $9.899M $-9.543M 0% $-0.12 $-9.794M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.352M ▼ $15.057M ▼ $14.942M ▲ $115K ▼
Q2-2025 $14.626M ▼ $19.974M ▲ $13.885M ▲ $6.089M ▼
Q1-2025 $15.303M ▼ $19.702M ▼ $13.208M ▼ $6.494M ▲
Q4-2024 $15.942M ▼ $20.187M ▼ $14.204M ▼ $5.983M ▼
Q3-2024 $19.598M $24.262M $15.205M $9.057M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-14.4M ▼ $-6.651M ▼ $-7K ▼ $4.138M ▼ $-2.274M ▼ $-6.658M ▼
Q2-2025 $-6.165M ▲ $-5.471M ▲ $0 $5.373M ▼ $-677K ▼ $-5.471M ▲
Q1-2025 $-6.687M ▲ $-6.498M ▲ $0 ▲ $5.89M ▲ $-639K ▲ $-6.498M ▲
Q4-2024 $-8.017M ▲ $-7.846M ▼ $-6K ▲ $3.339M ▲ $-3.656M ▲ $-7.852M ▼
Q3-2024 $-9.543M $-4.832M $-32K $-173K $-5.252M $-4.864M

Five-Year Company Overview

Income Statement

Income Statement Income statement Oncolytics is still a pure research-stage biotech, so it has effectively no product revenue. Its income statement is dominated by ongoing research and administrative expenses, which lead to steady annual losses. Those losses have been fairly consistent over the past several years, suggesting a stable but persistent cost base rather than rapidly escalating spending. Earnings per share remain negative, which is typical for a company at this stage that is funding clinical trials but not yet selling an approved drug.

Balance Sheet

Balance Sheet Balance sheet The company runs with a very lean balance sheet. Total assets are small and mostly made up of cash and equivalents, with little in the way of physical assets. Importantly, there is no financial debt reported, which reduces interest and refinancing risk but also highlights that the company relies mainly on equity funding and possibly grants or partnerships. Shareholders’ equity has been drifting down as losses accumulate, a normal pattern for a pre-revenue biotech but also a reminder that future capital raises are likely if trials continue for several more years.

Cash Flow

Cash Flow Cash flow Cash flows reflect a classic early-stage biotech profile: money steadily flows out to fund clinical trials, staff, and overhead, with no offsetting inflows from product sales. Operating cash burn has been relatively consistent, and the company spends virtually nothing on capital equipment, so almost all cash use is tied directly to operations and R&D. This makes the business highly sensitive to its cash balance and access to new funding. Without new capital, ongoing losses would gradually erode the existing cash, so the timing and terms of future financings or partnerships are important risk factors.

Competitive Edge

Competitive Edge Competitive position Oncolytics competes in a very crowded and fast-moving cancer immunotherapy space, but it has a distinct niche. Its lead asset, pelareorep, is an intravenously delivered oncolytic virus designed to make tumors more responsive to immune attack. The ability to turn “cold” tumors “hot” and to treat hard-to-reach or metastatic tumors via systemic delivery is a key differentiator versus therapies that must be injected directly into tumors. The company also benefits from a substantial patent estate, a long track record of clinical work, and collaborations with large pharma players. On the other hand, it is a small company with one primary asset, operating against much larger and better-funded competitors, and its long-term position depends heavily on successful trial outcomes and its ability to secure strong commercial partners.

Innovation and R&D

Innovation and R&D Innovation & R&D Innovation is the core of Oncolytics’ value. Pelareorep is a novel, naturally occurring virus used as a therapy rather than a traditional drug. Its mechanism aims to both kill cancer cells and reshape the tumor environment so other immunotherapies work better. The company has built deep expertise around this single platform, running multiple trials across cancers such as pancreatic and breast cancer and exploring use in other gastrointestinal tumors. Regulatory fast-track designations in certain indications suggest regulators see significant medical need and potential. However, the R&D strategy is highly concentrated: most of the scientific and financial risk is tied to one main program. Success in pivotal and late-stage trials could transform the company’s prospects, while setbacks would be particularly painful given the lack of diversification in the pipeline.

Summary

Summary Oncolytics Biotech is a classic clinical-stage oncology biotech: scientifically interesting, but financially dependent on external capital and trial success. The company has no product revenue and posts steady, moderate losses each year as it funds research and clinical studies. Its balance sheet is light but clean, with no debt and a cash position that needs to be watched closely relative to its ongoing burn. Competitively, it has a differentiated approach with pelareorep, supported by patents, safety data, and notable partnerships, but faces intense competition and the usual binary risks of drug development. The main drivers of future value will be clinical results and regulatory progress in key cancers—especially pancreatic and breast cancer—along with the company’s ability to secure supportive partnerships and financing on acceptable terms.

NEWS

November 20, 2025 · 4:05 PM UTC

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Read more

November 19, 2025 · 9:00 AM UTC

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Read more

October 28, 2025 · 7:30 AM UTC

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Read more

October 20, 2025 · 9:00 AM UTC

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Read more

September 29, 2025 · 8:30 AM UTC

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Read more